Literature DB >> 3299396

Effects of the dopamine D-1 antagonist SCH 23390 and the D-2 antagonist sulpiride on saline acceptance-rejection in water-deprived rats.

D B Gilbert, S J Cooper.   

Abstract

Separate groups of water-deprived rats were familiarized with drinking water or one of a range of NaCl solutions (0.45-2.7%) in a 30 min test. The substituted benzamide, sulpiride, a selective dopamine D-2 receptor antagonist, significantly increased the consumption of water and hypotonic saline at 30 mg/kg. In contrast, the selective dopamine D-1 receptor antagonist, SCH 23390 (0.01-0.1 mg/kg SC) significantly reduced the intake of water and of saline at different concentrations in a dose-dependent manner. Consumption of water and 0.45% saline were most sensitive to the antidipsogenic effect of SCH 23390. These results suggest that previously-reported antidipsogenic effects of neuroleptics may depend, to at least some degree, on dopamine D-1 receptor blockade. The increase in drinking produced by sulpiride indicates that dopamine may act at D-2 receptors to inhibit the consumption of water and hypotonic saline, but not of stronger salt solutions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3299396     DOI: 10.1016/0091-3057(87)90597-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Effects of dopamine receptor antagonists on sucrose consumption and preference.

Authors:  R Muscat; P Willner
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Role of dopamine D1-like and D2-like receptors in the activation of ingestive behaviour in thirsty rats licking for water.

Authors:  Paolo S D'Aquila; Domenico Elia; Adriana Galistu
Journal:  Psychopharmacology (Berl)       Date:  2019-07-04       Impact factor: 4.530

3.  Effects of the dopamine D1 receptor antagonist SCH 39166 on the ingestive behaviour of alcohol-preferring rats.

Authors:  I Panocka; R Ciccocioppo; M Mosca; C Polidori; M Massi
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.